Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Willow Biosciences (WLLW) has appointed Dr. Joseph Tucker as Chief Operating Officer
  • The company also announced the appointment of Dr. Peter Seufer-Wasserthal, who will replace Dr. Tucker as Chairman of the Board
  • Willow’s current focus is on the production of cannabinoids for the treatment of various illnesses and disorders, including pain, anxiety and obesity
  • Shares in the company are currently trading at C$0.75, with a market cap of C$59.17 million

Calgary-based Willow Biosciences (WLLW) has announced the appointment of Dr. Joseph Tucker as the company’s Chief Operating Officer.

As a result of his new role, Dr. Tucker will step back from his position as Executive Chairman and will be replaced by Dr. Peter Seufer-Wasserthal who will take over as independent Chairman of the Board.

Dr. Tucker has served as CEO, CFO and Vice President of several private and public biotech companies, facilitating a range of functions from acquisitions to stock market listings. He received a PhD in Biochemistry and Molecular Biology from the University of Calgary.

Dr. Tucker will retain his position on the board as a director.

“With our recent move to the TSX, we have taken steps to enhance the independence of our board of directors. Dr. Tucker’s new role as Chief Operating Officer is a continuation of his operational role when he was Executive Chairman,” said Willow President and CEO, Trevor Peters.

New Chairman, Dr. Seufer-Wasserthal, brings more than 25 years’ experience in the technology and biotechnology sector, and is currently Chief Commercial Officer of Origenis GmbH. He has also acted as Vice President of Business Development at Intrexon Corporation, and received his PhD from the Technical University of Graz.

Willow Biosciences’ current focus is on the production of cannabinoids for the treatment of pain, anxiety, obesity, brain disorders and other significant conditions and illnesses.

Shares in the company are currently trading at C$0.75, with a market cap of C$59.17 million.

More From The Market Herald

" Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Revive Therapeutics (RVV) announced an update of its Food and Drug Administration (FDA) phase three clinical trial for Bucillamine.
The Market Herald Video

" BioVaxys (CSE:BIOV) signs binding term sheet for distribution of Papilocare in the U.S.

BioVaxys Technology Corp. (BIOV) has signed a binding term sheet with Procare Health Iberia, S.L. of Barcelona, Spain.

" Satellos Bioscience (TSXV:MSCL) announces OTCQB listing

Common shares of Satellos Bioscience (MSCL) have commenced trading on the OTCQB Venture Market (OTCQB) under the symbol MSCLF.
Innocan Pharma - CEO Iris Bincovish

" Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Innocan Pharma’s (INNO) patent application, which claims cannabinoid-based topical compositions can treat psoriasis of the scalp, has reached the national phase.